Advanced searches left 3/3

Treatment Trial - Arxiv

Summarized by Plex Scholar
Last Updated: 06 July 2022

* If you want to update the article please login/register

Accurate collection of reasons for treatment discontinuation to better define estimands in clinical trials

The current case report form incorporates the underlying reasons for treatment discontinuation and who makes the decision for discontinuation of therapy, often resulting in an inaccurate series of reasons for discontinuation. Different reasons for treatment discontinuation were sometimes selected for the same underlying reason for treatment discontinuation, according to our analysis, due to the numerous choices for treatment discontinuation available in the CRF. Further work remains to be done to bring the training into the Clinical Data Interchange Standards Consortium's framework.

Source link: https://arxiv.org/abs/2206.01659v1


Unbiased and Efficient Estimation of Causal Treatment Effects in Cross-over Trials

With a focus on Thorough QT studies, we can extend causal inference reasoning to cross-over trials. We show that unbiased estimates of a causal treatment effect are obtained by a G-computation strategy in combination with weighted least squares results from a working regression model, as well as weighted least squares predictions. Even though a large number of Gaussian linear mixed working models lead to objective estimates of a causal treatment effect, even though they do not accurately represent the actual data generating mechanism. In a simulation study in which data are simulated from a complex data processing scheme with input parameters estimated on a real TQT data set, we compare a variety of working regression models. For all practical needs, working models adjusted for baseline QTc measurements have similar results in this setting.

Source link: https://arxiv.org/abs/2205.14995v1


Large-scale Virtual Clinical Trials of Closed-loop Treatments for People with Type 1 Diabetes

Prior to a human trial, we recommend a virtual clinical trial for determining the safety and efficacy of closed-loop diabetes drugs. We build a virtual clinical trial with high-performance computing and hardware, and we display an example trial with two mathematical models of one-million participants over 52 weeks, which can be completed in 2h 9 minutes.

Source link: https://arxiv.org/abs/2205.01332v1

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions